The Baidu-backed advanced chemicals developer secured $11.4m in a series A round featuring Novo with a targeted close of $15m.

Pharmaceutical firm Novo led the $11.4m first close of a series A round for US-based advanced chemicals and materials developer Kebotix yesterday.

The company did not disclose the identities of the other participants in the round, which has a $15m target for its close according to a regulatory filing.

Founded in 2017, Kebotix is developing new molecules and materials for medical and industrial projects using an artificial intelligence-powered laboratory.

The series A funding will strengthen the company’s operational capacity, helping…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?